Giazo (balsalazide disodium tablet) / Bausch Health - LARVOL DELTA

Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database. (PubMed, Expert Opin Drug Saf) - "Disproportionality analysis revealed that the top 5 drugs by ROR were phendimetrazine tartrate (ROR 104.64), trimethoprim + sulfamethoxazole (ROR 67.65), aldesleukin (ROR 52.67), mesalazine (ROR 49.73), and balsalazide disodium (ROR 45.26)...Through comprehensive analysis of the FAERS database, our study identified drugs with a strong signal for myocarditis that are not currently indicated on their labels. The findings suggest that the potential risk of myocarditis associated with these medications is significant and warrants close monitoring in clinical practice."

Journal • Cardiovascular • Inflammation

Smart crystalline framework materials with a triazole carboxylic acid ligand: fluorescence sensing and catalytic reduction of PNP. (PubMed, Dalton Trans) - "Based on functional properties, it is found that complex 1 exhibits excellent detection ability for small-molecule drugs (azithromycin, colchicine and balsalazide disodium) and actinide cations (Th and UO) within a lower concentration range without interference from other components. In addition, complexes 2 and 3 exhibited excellent catalytic reduction performance toward p-nitrophenol (PNP), with a reduction efficiency exceeding 98%. These experimental results evidence that complexes 1-3 have potential application prospects in fluorescence sensing and catalytic reduction."

Journal

Multiple Stimulus Response 2D Framework Constructed by a Flexible Cyclotriphosphazene-Derived Carboxylic Acid Linker: Synthesis, Characterization, and Fluorescence Sensing to Phenolic Pollutants and Small-Molecule Drugs. (PubMed, Inorg Chem) - "At the same time, the compound also exhibited nice trace detection ability for small-molecule drugs (moxifloxacin hydrochloride, balsalazide disodium, and colchicine); the limits of detection were all lower than 0.2 μM. These experimental results fully demonstrated the potential application value of 1 as a multifunctional fluorescent sensor."

Journal

Integrated Photoresponsive Alkaline Earth Metal Coordination Networks: Synthesis, Topology, Photochromism and Photoluminescence Investigation. (PubMed, Chemistry) - "In addition, the CNs also exhibited reusable photoluminescence turn-off toward drug molecules, balsalazide disodium (Bal.) and colchicine (Col.), with a nice limit of detection of 0.16 and 0.70 μM. Therefore, the AEM-CNs provided a design idea of integrated photoresponsive materials. We believe that related study would be further improved in near future."

Journal

[VIRTUAL] Could CD45 have a role in the development of myeloid malignancies? (BSH-I 2020) - "We identified that three drugs, Alendronate, Allopurinol and Balsalazide, may have the potential to act as CD45 inhibitors. The combination of these drugs with Cytarabine has indicated some degree of synergy. In conclusion, CD45 is highly expressed in AML cell lines and the inhibition of the gene, by siRNA or novel repurposed agents targeting CD45, have given an insight into the molecular pathways and potential therapeutic options associated with this gene."

Acute Myelogenous Leukemia • Hematological Malignancies • Immunology • Leukemia • Oncology • GLI2 • PTPRC

In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA lowering is associated with haematological changes. (PubMed, Diabet Med) - "In this observational, population-based study, sulfasalazine initiation was associated with a 6-month reduction in HbA1c. This correlated with haematological changes suggesting haemolytic effects of sulfasalazine. Haemolysis is proposed to contribute to HbA1c-lowering through the sulfonamide pharmacophore. This suggests that HbA1c is not a reliable measure of glycaemia in individuals prescribed sulfasalazine."

Clinical • Journal • Diabetes • Hematological Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

A chromatographic approach to development of 5-aminosalicylate/folic acid fixed-dose combinations for treatment of Crohn's disease and ulcerative colitis. (PubMed, Sci Rep) - "In this work, 5-aminosalicylates (mesalazine, balsalazide, sulfasalazine and olsalazine) and folic acid were characterized regarding their pharmacokinetic related properties (hydrophobicity, phospholipid and plasma protein binding) using the biomimetic chromatographic approach. Separation of all compounds was achieved within 16 min with satisfactory resolution (R > 3.67) using the XBridge Phenyl column (150 × 4.6 mm, 3.5 µm). High linearity (r > 0.9997) and precision (RSD < 2.29%) was obtained, whilst all recoveries were within the regulatory defined range by British (100.0 ± 5.0%) and United States Pharmacopeia (100.0 ± 10.0%)."

Journal • Colorectal Cancer • Crohn's disease • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Solid Tumor • Ulcerative Colitis

[VIRTUAL] COVID-19 and Ulcerative Colitis in Pregnancy (ACG 2020) - "She was diagnosed in 2015 and established care with us in 2018 while on balsalazide...She was started on budesonide 9mg daily, however due to persistent symptoms 2 weeks later, was switched to prednisone 40mg daily with clinical response within 72 hours...With collaboration with her obstetrics team, the decision was made to proceed with vedolizumab after delivery...Cautious treatment of maternal IBD is necessary. A multidisciplinary approach between IBD gastroenterology and Obstetrics is critical in safely managing these patients."

Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Obstetrics • Pain • Ulcerative Colitis

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. (PubMed, Cochrane Database Syst Rev) - "There is high-certainty evidence that 5-ASA is superior to placebo for maintenance therapy in UC. There is high-certainty evidence that 5-ASA is inferior compared to SASP. There is probably little or no difference between 5-ASA and placebo, and 5-ASA and SASP in commonly reported AEs such as flatulence, abdominal pain, nausea, diarrhea, headache, and dyspepsia. Oral 5-ASA administered once daily has a similar benefit and harm profile as conventional dosing for maintenance of remission in quiescent UC."

Clinical • Journal • Review • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • Ulcerative Colitis

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. (PubMed, Cochrane Database Syst Rev) - "There is high-certainty evidence that 5-ASA is superior to placebo, and moderate-certainty evidence that 5-ASA is not more effective than SASP. Considering relative costs, a clinical advantage to using oral 5-ASA in place of SASP appears unlikely. High-certainty evidence suggests 5-ASA dosed once daily appears to be as efficacious as conventionally-dosed 5-ASA. There may be little or no difference in efficacy or safety among the various 5-ASA formulations."

Clinical • Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • Ulcerative Colitis

Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations. (PubMed, Eur J Med Chem) - "Further in-vitro characterization in a trypsin coupled assay determined that the tested inhibitors showed no competition towards NAD or the synthetic substrate analogue ZKsA. In addition, investigations for subtype selectivity revealed that balsalazide is a subtype-selective Sirt5 inhibitor, and our initial SAR and docking studies pave the way for further optimization."

Journal

Organic anion transporting polypeptide 2B1 (OATP2B1), an expanded substrate profile, does it align with OATP2B1's hypothesized function? (PubMed, Xenobiotica) - "Some compounds previously reported to be OATP2B1 substrates in the literature, aliskiren, erlotinib, montelukast, fexofenadine, and taurocholate could not be confirmed as substrates.Literature describing in vivo outcomes for OATP2B1 substrates, coproporphyrin III, ARBs, balsalazide, olsalzine, and gavestinel highlight the absence of a substantial impact of OATP2B1 on the oral absorption and/or brain penetration of OATP2B1 substrates. Suggestions of including OATP2B1 assessment as part of the drug approval process are likely premature and further mechanistic work with more robust OATP2B1 substrates, which may include some of those described here, is desirable."

Journal

"13/ Newer 5-ASA without Sulfa (mesalamine, olsalazine, balsalazide) ✔️Well tolerated ✔️Oral or topical ✔️Induction + maintenance ✔️Big several pills to take -> affect compliance" (@mjayoushe)

Clinical

Gut microbiota-driven drug metabolism in inflammatory bowel disease. (PubMed, J Crohns Colitis) - "The human intestinal microbiota can have a major impact on drug metabolism and efficacy of medication prescribed in inflammatory bowel disease practice. A better understanding of these interactions between microbiota and drugs is needed and should be an integral part of the drug development pathway of new inflammatory bowel disease medication."

Journal • Gastroenterology • Immunology • Inflammatory Bowel Disease

"Balsalazide can be opened but it makes an orange mess!" (@DrRosenIBD)

Salix Announces early termination of HSR waiting period for pending transaction (Salix Press Release) - "Salix...announced that it has received notice of the early termination of the waiting period for U.S. antitrust review...Completion of the transaction remains subject to approval by Salix’s stockholders and certain other closing conditions."

Anticipated M & A • Inflammatory Bowel Disease

A Sausage-Shaped Pancreas That Isn’t Autoimmune Pancreatitis (ACG 2018) - "...He was on adalimumab and balsalazide, started 8 weeks ago...Immunological work-up revealed negative antinuclear antibodies and IgG4 level of 54 mg/dL.The patient was started on prednisone for presumed autoimmune pancreatitis...However, lack of dramatic response to steroids, recurrence of pancreatitis with resumption of balsalazide and lack of recurrence since stopping it confirm the presence of drug-induced pancreatitis. This demonstrates that a sausage-shaped pancreas in this case does not imply autoimmune pancreatitis."

Biosimilar • Hepatology • Pain • Pancreatitis • Ulcerative Colitis

Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease. (PubMed, Inflamm Bowel Dis) - "About 1 in 3 privately insured patients with CD received 5-ASA prescriptions despite their questionable effectiveness; however, in an encouraging trend, prescription rates significantly decreased from 2009 to 2014. This high prescription rate may reflect a gap in providers' knowledge regarding the available evidence-an opportunity for cost savings with improved health care delivery."

Clinical • Journal • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells. (PubMed) - "Combination treatment with PT and balsalazide may offer an effective strategy for the induction of apoptosis in HCT116 cells."

Journal • Biosimilar • Colorectal Cancer • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology

Could CD45 have a role in the development of myeloid malignancies? (BSH 2020) - "We identified that three drugs, Alendronate, Allopurinol and Balsalazide, may have the potential to act as CD45 inhibitors. The combination of these drugs with Cytarabine has indicated some degree of synergy. In conclusion, CD45 is highly expressed in AML cell lines and the inhibition of the gene, by siRNA or novel repurposed agents targeting CD45, have given an insight into the molecular pathways and potential therapeutic options associated with this gene."

Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • GLI2

Outcomes of a drug shortage requiring switching in patients with ulcerative colitis. (PubMed, World J Gastrointest Pathophysiol) - "This study of a balsalazide shortage in UC patients exemplifies the detrimental impact of a drug shortage on long term patient, disease and commercial outcomes."

Clinical • Journal • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Comparative assessment of probiotics and standard therapies for mild to moderate ulcerative colitis: A systematic review and network meta-analysis (ECCO-IBD 2020) - "We included randomised controlled trials (RCTs) in patients with mild to moderate UC that compared probiotics, sulfasalazine, mesalamine (low dose <2 g/day, standard dose ≥ 2 g/day), olsalazine, balsalazide, budesonide, budesonide MMX and beclomethasone either alone or in combination with topical therapy, to each other or placebo. Probiotics were ranked the best tolerated option in terms of discontinuation due to adverse events (SUCRA 0.80).Conclusion Probiotics are well tolerated but they are not effective in inducing remission in active UC. They may be effective when added to mesalamine therapy in preventing relapse of quiescent UC, but large, well-designed RCTs are needed."

Retrospective data • Review

Coexistence of Lymphocytic Colitis in a Patient With Ulcerative Colitis (ACG 2019) - "Patient was started on budesonide in addition to balsalazide with reduction in stool frequency and improvement in consistency. Here we describe a case of active UC further complicated by lymphocytic colitis which was successfully managed with a combination of a 5-aminosalicyclic-acid derivative and glucocorticoids. This case emphasizes the importance of looking for alternative causes of symptoms in patients with mild colonoscopic findings."

Clinical

Management of Severe Ulcerative Colitis in a Patient With Familial Dysautonomia (ACG 2019) - "She had been maintained on balsalazide...Infliximab and cyclosporine were opposed due to infection risk and later exhibiting possible nephrotoxicity...Due to the gut-specificity of vedolizumab, infection risk is considerably reduced compared to that of other biologics and is the most favorable option in the setting of underlying FD. This case highlights the difficulty encountered when treating IBD in the setting of systemic illness and underscores the need to carefully consider management options to enhance patient outcomes."

Clinical

Development of an effective fluorescence probe for discovery of aminopeptidase inhibitors to suppress biofilm formation. (PubMed, J Antibiot (Tokyo)) - "Through screening of an in-house chemical library, a commercially available drug, balsalazide, has been identified as a novel PaAP inhibitor, which exhibited remarkable anti-biofilm effect. Our study indicated that the newly developed fluorescence probe is applicable in exploring new aminopeptidase inhibitors, and it also warrants further investigation of balsalazide as a new anti-biofilm agent to treat P. aeruginosa infection in combination with known antibiotics."

Journal